DocTalk returns in 2022 with a discussion of the recent Food and Drug Administration (FDA) approval of tralokinumab for the treatment of moderate-to-severe atopic dermatitis in adult patients. 

For this episode, Jonathan Silverberg, MD, PhD, MPH, discusses the ECZTRA trials, 3 phase 3 trials that evaluated the efficacy of the biologic as a monotherapy as well as a combination therapy with topical corticosteroids.

Tralokinumab is the first and only biologic approved by the FDA that binds to and inhibits the interleukin (IL)-13 cytokine, noted as a key driver of signs and symptoms of atopic dermatitis. Dr. Silverberg speaks on what this new treatment means for the future of atopic dermatitis management.